Pratteln, Switzerland, November 11, 2020 - Santhera Pharmaceuticals (SIX: SANN) announces that Dario Eklund, Chief Executive Officer, and Andrew Smith, Chief Financial Officer, will present at the Jefferies Virtual London Healthcare Conference at 11:10 GMT on November 17, 2020.
Executive management will present an overview of Santhera's strategic focus and latest developments in moving forward with its lead development compound vamorolone for the treatment of Duchenne muscular dystrophy and will host one-to-one meetings.
About Santhera
Santhera Pharmaceuticals.
Raxone is a trademark of Santhera Pharmaceuticals.
For further information please contact:
public-relations@santhera.comor
Eva Kalias, Head External Communications
Phone: +41 79 875 27 80
eva.kalias@santhera.com
# # #
Attachment
- 2020-11-10_InvestorConference_e_final (https://ml-eu.globenewswire.com/Resource/Download/cfd1ca3b-bd65-4edc-af43-e1fb4368332f)
